You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
同方康泰(01312.HK)附属原料药证实就对抗武汉肺炎有一定疗效
阿思达克 02-03 22:54

同方康泰(01312.HK)公布,集团接获工业和信息化部消费品司、重庆市经济和信息化委员会与重庆市长寿区经济和信息化委员会的通知,磷酸氯(口奎)(Chloroquine Phosphate)被测试及证实就对抗新型冠状病毒感染的肺炎有一定的疗效。

公司非全资附属康乐制药早前已获国家药品监督管理局认可为生产原料药磷酸氯(口奎)(Active Pharmaceutical Ingredients Chloroquine Phosphate)的单位。而因应新型冠状病毒的爆发,其已恢复生产及制作原料药磷酸氯(口奎)。同时,集团获进一步通知康乐制药被认可生产的原料药磷酸氯(口奎)现已被纳入中央医药储备的名单中。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account